8-K: Precipio Announces Q1 2025 Financial Results, Highlights Strong Revenue Growth and Improved Efficiency

Precipio reports a 43% year-over-year revenue increase in Q1 2025, driven by growth in both its Products and Pathology Services divisions, alongside significant improvements in adjusted EBITDA and cash flow.

Summary

• Precipio, Inc. announced its Q1 2025 financial results, showcasing significant year-over-year growth.
• Revenues reached $4.9 million, a 43% increase compared to Q1 2024.
• However, revenues decreased 9.5% from Q4 2024 due to seasonal factors and onboarding delays.
• Adjusted EBITDA improved significantly to ($108K) from ($1,409K) year-over-year, a 92% improvement.
• The company saw a 93% improvement in cash used in operations, with a change of ($44K) in Q1 2025 compared to ($667K) in Q1 2024.
• Net cash used in Q1 2025 was ($372K), a 49% improvement from ($726K) in Q1 2024.
• The Products division successfully onboarded one new customer and launched two new panels.
• The Pathology Services division experienced a 54% revenue increase and a 46% test volume increase year-over-year.
• Precipio received MolDx approval for NGS testing, enabling Medicare billing.
• Overall gross margins increased from 27% to 43% year-over-year.
• Operating expenses as a percentage of net revenue decreased from 87% to 61% year-over-year.
• Management anticipates a return to positive operating cash flow by Q2 or Q3 2025.
• The company expects continued revenue growth and improved results throughout 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth, significant improvements in adjusted EBITDA and cash flow, and positive outlook for the rest of the year. However, the company is still operating at a loss, and there are risks associated with achieving future financial targets.

Positives

• Significant revenue growth of 43% year-over-year in Q1 2025.
• Substantial improvement in adjusted EBITDA, reducing losses by 92% year-over-year.
• Considerable improvement in cash used in operations, decreasing by 93% year-over-year.
• Strong growth in the Pathology Services division, with a 54% revenue increase and a 46% test volume increase.
• Increase in gross margins across both Products and Pathology Services divisions.
• Reduction in operating expenses as a percentage of net revenue, indicating improved efficiency.
• MolDx approval for NGS testing, opening up Medicare billing opportunities.
• Receipt of $400,000 in non-recurring income from a refundable employee retention credit.

Negatives

• Revenue decreased by 9.5% from Q4 2024 due to seasonal factors and onboarding delays.
• The company is still operating at a loss, with an adjusted EBITDA of ($108K) for Q1 2025.
• Net cash used in Q1 2025 was ($372K), although this is an improvement from the previous year.

Risks

• The company's financial outlook is subject to various risks, assumptions, and uncertainties that may cause actual outcomes to differ materially.
• Seasonal delays in pathology revenues and temporary delays in customer onboarding and operational ramp-up can impact financial performance.
• The company's ability to achieve positive operating cash flow in Q2 or Q3 2025 is not guaranteed and depends on various factors.

Future Outlook

Precipio anticipates continued revenue growth and a return to positive operating cash flow by Q2 or Q3 2025, expecting 2025 to be a transformative year with scalable growth translating into improved results and long-term shareholder value.

Management Comments

• We remain confident in the Company's trajectory, supported by strong year-over-year revenue growth, improved gross margins, disciplined cost control and increasing operational efficiency, said Ilan Danieli, Precipio's CEO.
• With our expectation of momentum building in our Product business pipeline, as well as the expanded reimbursement opportunities in Pathology Services, we anticipate continued revenue growth and a return to positive operating cash flow by Q2 or Q3.
• We believe 2025 will be a transformative year in which scalable growth translates into improved results and long-term shareholder value.

Industry Context

Precipio operates in the competitive cancer diagnostics market, where companies are focused on developing and commercializing innovative diagnostic products and services. The MolDx approval for NGS testing is a significant milestone, as it allows Precipio to bill Medicare for these tests, potentially increasing revenue from the Medicare population. The reversal of the FDA ruling regarding Laboratory Developed Tests (LDTs) also benefits Precipio, as it removes a barrier that concerned certain laboratories.

Comparison to Industry Standards

• Comparing Precipio's 43% revenue growth to other small-cap diagnostic companies, this growth rate is relatively strong, suggesting effective market penetration and product adoption.
• The improvement in adjusted EBITDA and cash flow indicates better operational efficiency and cost management, which are crucial for long-term sustainability.
• Gross margin improvements from 27% to 43% are also positive, but further improvements are needed to align with industry leaders like Exact Sciences (EXAS) or Guardant Health (GH), which typically have gross margins above 70%.

Stakeholder Impact

• Shareholders can expect improved financial performance and potential for long-term value creation.
• Employees may benefit from the company's growth and improved financial stability.
• Customers can expect continued innovation and improved diagnostic solutions.
• The MolDx approval for NGS testing will benefit Medicare patients by providing access to advanced diagnostic testing.

Next Steps

• Management will provide more details on the company's quarterly performance and outlook during the shareholder conference call on May 15, 2025.
• The company expects increased orders in Q2 and going forward for the Products division.
• Precipio anticipates that the MolDx approval for NGS testing will positively impact future revenue from Medicare populations.
• The company expects combined margins to continue to climb during 2025 as the revenue mix includes more product sales.

Key Dates

Keywords

financial results, cancer diagnostics, pathology services, products division, revenue growth, adjusted EBITDA, cash flow, Precipio, PRPO